• Molecular NameIloprost
  • Synonymiloprost
  • Weight360.494
  • Drugbank_IDDB01088
  • ACS_NO78919-13-8
  • Show 3D model
  • LogP (experiment)3.964
  • LogP (predicted, AB/LogP v2.0)3.76
  • pkaN/A
  • LogD (pH=7, predicted)1.66
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)-2.55
  • LogSw (predicted, AB/LogsW2.0)0.16
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors3
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds9
  • TPSA77.76
  • StatusFDA approved
  • AdministrationInhaled Intravenous
  • PharmacologyA drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and ischaemia
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability16.0
  • Protein binding60.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsm Iloprost is metabolized principally via β-oxidation of the carboxyl side chain. The main metabolite is tetranor-iloprost, which is found in the urine in free and conjugated form. In animal experiments, tetranor-iloprost was pharmacologically inactive.
  • Half life0.33~0.5 h
  • ExcretionN/A
  • Urinary Excretion12~18 (low dose: 1.5 g/m2) and 53.1 +/- 9.6 (high dose: 5 g/m2)
  • CleranceN/A
  • ToxicityOverdoses can lead to hypotension, headache, flushing, nausea, vomiting, and diarrhea.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A